Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC)
Autor: | C. Bachmann, Alfred Königsrainer, Iaroslav Sautkin, Giorgi Nadiradze, Rami Archid, Marc A. Reymond, Frank-Jürgen Weinreich |
---|---|
Rok vydání: | 2021 |
Předmět: |
Dynamic Manuscript
Hyperthermia medicine.medical_treatment Technology development Intraperitoneal chemotherapy 03 medical and health sciences 0302 clinical medicine Therapeutic Hyperthermia medicine Animals Humans Industrial Development Aerosol Aerosolization Aerosols Chemotherapy business.industry Hyperthermia Induced medicine.disease 030220 oncology & carcinogenesis Drug delivery Medical devices Cattle Laparoscopy 030211 gastroenterology & hepatology Surgery business Biomedical engineering |
Zdroj: | Surgical Endoscopy |
ISSN: | 1432-2218 0930-2794 |
DOI: | 10.1007/s00464-021-08567-y |
Popis: | Background Optimized drug delivery systems are needed for intraperitoneal chemotherapy. The aim of this study was to develop a technology for applying pressurized intraperitoneal aerosol chemotherapy (PIPAC) under hyperthermic conditions (hPIPAC). Methods This is an ex-vivo study in an inverted bovine urinary bladder (IBUB). Hyperthermia was established using a modified industry-standard device (Humigard). Two entry and one exit ports were placed. Warm-humid CO2 was insufflated in the IBUB placed in a normothermic bath to simulate body thermal inertia. The temperature of the aerosol, tissue, and water bath was measured in real-time. Results Therapeutic hyperthermia (target tissue temperature 41–43 °C) could be established and maintained over 30 min. In the first phase (insufflation phase), tissue hyperthermia was created by insufflating continuously warm-humid CO2. In the second phase (aerosolization phase), chemotherapeutic drugs were heated up and aerosolized into the IBUB. In a third phase (application phase), hyperthermia was maintained within the therapeutic range using an endoscopic infrared heating device. In a fourth phase, the toxic aerosol was discarded using a closed aerosol waste system (CAWS). Discussion We introduce a simple and effective technology for hPIPAC. hPIPAC is feasible in an ex-vivo model by using a combination of industry-standard medical devices after modification. Potential pharmacological and biological advantages of hPIPAC over PIPAC should now be evaluated. |
Databáze: | OpenAIRE |
Externí odkaz: |